Skip to content


Open Access

Antibody fingerprint

  • Jonathan B Weitzman
Genome Biology20034:spotlight-20030102-01

Published: 2 January 2003


Prostate CancerProstate Cancer PatientMetastatic Prostate CancerOnline PublicationClinical Prognosis

In an Advanced Online Publication in Nature Biotechnology, Paul Mintz and colleagues at the University of Texas M.D. Anderson Cancer Center in Texas, describe the use of phage-display technology to examine the repertoire of circulating, anti-tumour antibodies in the blood of prostate cancer patients (Nature Biotechnology, 23 December 2002, DOI:10.1038/nbt774). To characterise the 'fingerprint' of circulating antibodies they screened a phage random-peptide library with purified immunoglobulins from the serum of cancer patients and identified a number of immunoreactive peptide motifs. Reactivity correlated with disease progression and poor clinical prognosis. The anti-peptide antibodies recognise the glucose-regulated protein GRP78 which was also upregulated in metastatic prostate cancer.


  1. Nature Biotechnology, []
  2. University of Texas M.D. Anderson Cancer Center , []
  3. The glucose-regulated proteins: stress induction and clinical applications.Google Scholar


© BioMed Central Ltd 2003